Dane H. Slentz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dane H. Slentz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Christine C. Nelson
Department of Ophthalmology and Visual Sciences, W. K Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI USA
3 shared publicationsAdam S. Hassan
Eye Plastic & Facial Cosmetic Surgery, Grand Rapids, Michigan, U.S.A.
1 shared publicationPaul R. Lichter
Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, Ann Arbor, Michigan
1 shared publication- Terry J. Smith
University of Michigan Medical School
1 shared publication Victor M. Elner
Department of Ophthalmology and Visual Sciences, W. K Kellogg Eye Center, Ann Arbor, Michigan, U.S.A.
1 shared publication
Latest Publications
- 10 June 2020
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (7) , 645-649
Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy
Introduction: Thyroid-associated ophthalmopathy (TAO) is a disfiguring, potentially blinding, and sub-optimally managed autoimmune condition. Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in 2 clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO. Areas Covered: This article reviews phase II and III placebo controlled, double masked, prospective, multicenter studies assessing the efficacy and safety of teprotumumab for the treatment of active, moderate-to-severe TAO. Expert Opinion: Teprotumumab has demonstrated substantial and rapid improvement in Clinical Activity Score and proptosis reduction in TAO compared to placebo. Subjective diplopia and quality of life were also improved in both clinical trials. Teprotumumab exhibited a favorable safety profile, with transient hyperglycemia, muscle cramps, and auditory side effects being associated with the drug; these were usually transient. The trial findings indicate that teprotumumab is a promising, potential first line therapy for treating active TAO.
- 10 June 2020
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (7) , 645-649
Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy
Introduction: Thyroid-associated ophthalmopathy (TAO) is a disfiguring, potentially blinding, and sub-optimally managed autoimmune condition. Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in 2 clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO. Areas Covered: This article reviews phase II and III placebo controlled, double masked, prospective, multicenter studies assessing the efficacy and safety of teprotumumab for the treatment of active, moderate-to-severe TAO. Expert Opinion: Teprotumumab has demonstrated substantial and rapid improvement in Clinical Activity Score and proptosis reduction in TAO compared to placebo. Subjective diplopia and quality of life were also improved in both clinical trials. Teprotumumab exhibited a favorable safety profile, with transient hyperglycemia, muscle cramps, and auditory side effects being associated with the drug; these were usually transient. The trial findings indicate that teprotumumab is a promising, potential first line therapy for treating active TAO.
- 1 May 2020
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 36 (3) , e70-e73
Supernumerary Lacrimal Caruncle: A Case Series
A 12-year-old boy and 63-year-old woman were incidentally found to have a solitary, well-defined, raised, ovoid lesion involving the inferomedial palpebral conjunctiva. Both lesions were separate from the lacrimal caruncle with normal conjunctiva surrounding the lesions. Excisional biopsies were consistent with caruncular tissue. In the English literature, supernumerary lacrimal caruncle has only been previously described in adults despite the congenital nature of the lesion.
- 1 May 2020
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 36 (3) , e70-e73
Supernumerary Lacrimal Caruncle: A Case Series
A 12-year-old boy and 63-year-old woman were incidentally found to have a solitary, well-defined, raised, ovoid lesion involving the inferomedial palpebral conjunctiva. Both lesions were separate from the lacrimal caruncle with normal conjunctiva surrounding the lesions. Excisional biopsies were consistent with caruncular tissue. In the English literature, supernumerary lacrimal caruncle has only been previously described in adults despite the congenital nature of the lesion.
- Open Access
- 1 September 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (9) , 1038-1044
Characteristics of Industry Payments to Ophthalmologists in the Open Payments Database
The Open Payments Database (OPD) was established by the Centers for Medicare & Medicaid Services (CMS) to report the financial interactions between the medical industry and health care professionals, as mandated by the Physician Payments Sunshine Act of 2010, part of the Patient Protection and Affordable Care Act. The 2018 report describes financial information between August 1, 2013, and December 31, 2017. During this period, the OPD reported that $32.49 billion dollars’ worth of research and general payments were distributed from the medical industry to physicians and teaching hospitals.1
- 1 September 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (9) , 1038-1044
Open AccessCharacteristics of Industry Payments to Ophthalmologists in the Open Payments Database
The Open Payments Database (OPD) was established by the Centers for Medicare & Medicaid Services (CMS) to report the financial interactions between the medical industry and health care professionals, as mandated by the Physician Payments Sunshine Act of 2010, part of the Patient Protection and Affordable Care Act. The 2018 report describes financial information between August 1, 2013, and December 31, 2017. During this period, the OPD reported that $32.49 billion dollars’ worth of research and general payments were distributed from the medical industry to physicians and teaching hospitals.1